Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1998 March;42(1) > The Quarterly Journal of Nuclear Medicine 1998 March;42(1):49-53

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES  BREAST CANCER II 

The Quarterly Journal of Nuclear Medicine 1998 March;42(1):49-53

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Optimized sentinel node scintigraphy in breast cancer

Paganelli G., De Cicco C., Cremonesi M., Prisco G., Calza P., Luini A.*, Zucali P.*, Veronesi U.*

From the Division of Nuclear Medicine *Division of Senology Istituto Europeo di Oncologia, Milan, Italy


PDF


Introduction. Axillary ­lymph ­node dis­sec­tion (­ALND) rep­re­sents an impor­tant stag­ing pro­ce­dure in the sur­gi­cal treat­ment of ­breast can­cer. However, it may ­result nec­es­sary in ­tumors of lit­tle dimen­sions ­because of low per­cent­age of met­a­stat­ic axil­lary ­lymph ­node (ALN). If a non inva­sive tech­nique pre­dict­ed the stat­us of ALN, ­ALND pro­ce­dures ­could be ­avoided. We car­ried out ­this ­study i) to estab­lish the ­best tech­nique to per­form the lym­phos­cin­tig­ra­phy for detect­ing the sentinel node in ­breast can­cer and ii) to deter­mine wheth­er a ­clear sen­ti­nel ­node reli­ably pre­dicts a dis­ease ­free axil­la.
Methods. 215 ­patients ­were sub­mit­ted to the lym­phos­cin­tig­ra­phy ­before sur­gery. Three dif­fer­ent col­loid­al radio­trac­ers ­with par­ti­cle ­size rang­ing ­between <50 and 1000 nm ­were inject­ed suder­mi­cal­ly or per­i­tu­mo­ral­ly. Early and ­late imag­es ­were record­ed in ante­ri­or and ­oblique pro­jec­tions and the SN was ­marked on the ­skin and biop­sied ­using a gam­ma detec­tion ­probe (GDP) dur­ing sur­gery.
Results. The SN was iden­ti­fied in 210/215 cas­es (97.6%). The SN accu­rate­ly pre­dict­ed axil­lary ALN stat­us in 204/210 (97.1%) ­patients in ­whom a sen­ti­nel ­node was iden­ti­fied and in all the cas­es (45 ­patients) ­with ­tumor <1.5 cm in diam­e­ter. In 38/101 cas­es ­with met­a­stat­ic axil­lary ­nodes (37.7%) the ­only pos­i­tive ­node was the SN.
Conclusions. Lymphoscintigraphy can eas­i­ly ­locate the SN in ­breast can­cer. SN detec­tion result­ed easi­er ­when ­large ­size micro­col­loids ­were ­used. Subdermally admin­is­tra­tion ­appeared the ­best way of injec­tion for pal­pa­ble ­lesions. Breast can­cer ­patients with­out clin­i­cal involve­ment of the axil­la ­should under­go SN biop­sy rou­tine­ly and this may allow sparing com­plete axil­lary dis­sec­tion ­when the SN is ­free of dis­ease.

inizio pagina